VolitionRx's Nu.Q® NETs Assay Chosen for €6.3M French Sepsis Detection Program — VolitionRx Limited (Volition)

Event summary

VolitionRx's Nu.Q® NETs Assay selected as the sole biomarker for the DETECSEPS program, a €6.3M French government-funded initiative to detect sepsis early.
The program, launched on September 17, 2026, aims to evaluate the assay's effectiveness in emergency departments to triage sepsis risk within one hour.
VolitionRx is collaborating with IDS France, which provides the IDS i10® automated analyzer for measuring the biomarker.
The DETECSEPS Consortium includes IHU SEPSIS, AP-HP, and HCL, with funding from the French Health Innovation Agency and Banque Publique d'Investissement.

The big picture

VolitionRx's participation in the DETECSEPS program underscores the growing emphasis on early disease detection through biomarkers. The €6.3M initiative reflects a strategic shift toward integrating advanced diagnostics into emergency care workflows, potentially reducing sepsis-related mortality and healthcare costs. With approximately 21 million sepsis-related deaths annually, the program's success could position VolitionRx as a key player in the multi-billion dollar diagnostic market for infectious diseases.

What we're watching

Clinical Validation: Whether the Nu.Q® NETs Assay can demonstrate sufficient accuracy and reliability in real-world emergency settings to justify broader adoption.
Market Expansion: The pace at which VolitionRx can replicate this program's success in other countries, given the global sepsis burden of 166 million cases annually.
Reimbursement Dynamics: How quickly healthcare systems and insurance plans will cover the Nu.Q® NETs Assay, which is critical for its commercial viability.